×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Yahoo Finance
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20%...
1 month ago
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout (NASDAQ:SLS)
Seeking Alpha
Summary · SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44%...
1 month ago
Sellas Life Sciences price target lowered to $6 from $9 at Ladenburg - TipRanks.com
Tipranks
Ladenburg analyst Aydin Huseynov lowered the firm's price target on Sellas Life Sciences to $6 from $9 and keeps a Buy rating on the shares.
4 days ago
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid...
1 week ago
Sellas sends 2 execs packing while awaiting phase 3 cancer vax readout
Fierce Biotech
Sellas Life Sciences Group is sending two executives out the door as part of efforts to optimize resources around advancing its clinical...
2 months ago
Sellas Life Sciences Shares Drop 31% After Direct Offering Prices
MarketWatch
By Chris Wack Sellas Life Sciences Group shares were down 31% at $1.07 after the company entered into definitive agreements with two...
2 months ago
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Yahoo Finance
Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on the Phase 2a Clinical Trial of SLS009 in...
2 months ago
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following ...
GlobeNewswire
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer...
3 weeks ago
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at ...
Yahoo Finance
All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR)...
2 months ago
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
GlobeNewswire
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage...
4 months ago